Search
Tacrolimus
go.drugbank.com/drugs/DB00864ApprovedInvestigationalTacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparatio...
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsProducts: Envarsus Pa, TACROLIMUS MYLAN GENERICSSodium bicarbonate
go.drugbank.com/drugs/DB01390ApprovedInvestigationalSodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.
Human immunoglobulin G
go.drugbank.com/drugs/DB00028ApprovedInvestigationalIntravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and io...
Products: INTRAGAM P, BERIGLOBINA - PVusolimogene oderparepvec
go.drugbank.com/drugs/DB23008ApprovedInvestigational] The FDA granted vusolimogene oderparepvec-wtpg accelerated approval on August 6, 2026, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed on a PD … L64062] It is the second oncolytic viral therapy approved in the United States, following talimogene laherparepvec (T-VEC, Imlygic) in 2015, and the first approved for melanoma that has progressed on anti-PD
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational-1/PD-L1 inhibitor therapy. … [L64775] On July 29, 2026 it extended the authorization to first-line treatment of adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy
Categories: P-glycoprotein substratesRelatlimab
go.drugbank.com/drugs/DB14851ApprovedInvestigational[L41305] As immune checkpoint inhibitors have limited efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like … [A246155] Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor [nivolumab] in the combination product Opdualag (Bristol-Myers Squibb), for the treatment of unresectable or metastatic
Avelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigationalAvelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsAnthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalThis binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. … Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and
Ropeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigational[A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials. … [A242000, A242005] [Interferon alfa-2b] has been used for decades to treat PV but requires frequent dosing and is not tolerated by all patients.
Synonyms: PEG-P-IFN-alfa-2b, PEG-P-IFN-alpha-2bCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2A6 InhibitorsBelzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigational[L64571] On September 24, 2026, the FDA approved belzutifan in combination with lenvatinib for advanced ccRCC following a PD-1 or PD-L1 inhibitor.[L64572]
Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates